Published in: Genetic Engineering News
On: April 15, 1994
“Many biotechnology and pharmaceutical companies believe that new drug delivery systems will soon garner profits for those willing to stand by their nonconventional methods of pharmaceutical methods of pharmaceutical administration. Even biotech-produced proteins and peptides may soon find interesting avenues of drug delivery.
One of the most compelling technologies has emerged from Canji Inc. (San Diego, CA). Known for novel anticancer agents and gene therapies, Canji recently acquired a patented new technology for inserting and maintaining genes in mammalian cells.”